OTR3
OTR3 is a France-based biotechnology company focused on matrix therapy using synthetic heparan-sulfate mimetics to restore extracellular matrix structure and promote tissue regeneration. The company develops sterile topical medical and veterinary formulations and delivery systems, conducts preclinical research across multiple indications (dermatology, neurology, pulmonary, bone, ophthalmology, stomatology), and runs clinical trials including programs in acute ischemic stroke and ophthalmology. OTR3 operates under an ISO 13485 quality management system and maintains academic collaborations and grant-funded research projects.
Industries
Nr. of Employees
small (1-50)
Products
Cacipliq 20
Sterile topical matrix-therapy solution supplied as spray or kit; indicated for treatment of chronic, non-healing ulcers and other wound types. Classified as a Class III medical device in the EU.
Dermapliq Spray
Sterile topical spray based on matrix-mimetic technology for hygiene and management of skin lesions in animals; preservative-free veterinary product.
Clerapliq
Ophthalmic hygiene and corneal lesion management product for veterinary use formulated with matrix-mimetic agents in physiological serum, supplied as pipette strips and an ocular rinse.
OTR4132
A novel neuroprotector and matrix therapy medical device administered intra-arterially after successful endovascular thrombectomy for acute ischemic stroke.
OTR4120
A heparan sulfate mimetic therapy investigated for its antifibrotic potential and applications in regenerative medicine models.
Cacipliq 20®
Cacipliq 20® is a class III medical device and tissue regeneration solution based on RGTA technology, designed for rapid and effective wound healing in chronic, non-healing ulcers.
Cacipliq 20
Sterile topical matrix-therapy solution supplied as spray or kit; indicated for treatment of chronic, non-healing ulcers and other wound types. Classified as a Class III medical device in the EU.
Dermapliq Spray
Sterile topical spray based on matrix-mimetic technology for hygiene and management of skin lesions in animals; preservative-free veterinary product.
Clerapliq
Ophthalmic hygiene and corneal lesion management product for veterinary use formulated with matrix-mimetic agents in physiological serum, supplied as pipette strips and an ocular rinse.
OTR4132
A novel neuroprotector and matrix therapy medical device administered intra-arterially after successful endovascular thrombectomy for acute ischemic stroke.
OTR4120
A heparan sulfate mimetic therapy investigated for its antifibrotic potential and applications in regenerative medicine models.
Cacipliq 20®
Cacipliq 20® is a class III medical device and tissue regeneration solution based on RGTA technology, designed for rapid and effective wound healing in chronic, non-healing ulcers.
Services
Research, preclinical testing and clinical study support for matrix-therapy candidates across multiple indications.
Implementation and maintenance of QMS processes, supplier audits, batch release and materiovigilance for medical devices.
Research, preclinical testing and clinical study support for matrix-therapy candidates across multiple indications.
Implementation and maintenance of QMS processes, supplier audits, batch release and materiovigilance for medical devices.
Expertise Areas
- Tissue regeneration and matrix therapy
- Wound healing and chronic ulcer management
- Neuroprotection and stroke therapeutics
- Preclinical modeling and ex vivo assay development
Key Technologies
- Heparan sulfate mimetics
- Biomimetic polysaccharide polymers
- Matrix therapy approaches
- Ex vivo precision-cut lung slice (hPCLS) models
News & Updates
Announcement that a clinical trial (MATRISS II) evaluating an intra-arterial neuroprotective matrix-mimetic candidate achieved its primary endpoint in patients with acute ischemic stroke.
Publication reporting development and evaluation of collagen scaffolds functionalized with a heparan sulfate mimic and fibroblast growth factor 2.
Poster and oral presentation on generation of three-dimensional human precision-cut lung slices (hPCLS) for pulmonary fibrosis research.
Article describing the concept and clinical applications of matrix-mimetic agents for corneal and other tissue repair, authored by clinicians and researchers.
Reference to a clinical study on an ophthalmic application of matrix-mimetic therapy published in JAMA Ophthalmology addressing corneal disease outcomes.
Article summarizing a topical treatment study assessing efficacy and tolerance of a matrix-mimetic agent in neurotrophic keratopathy.
Announcement that a clinical trial (MATRISS II) evaluating an intra-arterial neuroprotective matrix-mimetic candidate achieved its primary endpoint in patients with acute ischemic stroke.
Publication reporting development and evaluation of collagen scaffolds functionalized with a heparan sulfate mimic and fibroblast growth factor 2.
Poster and oral presentation on generation of three-dimensional human precision-cut lung slices (hPCLS) for pulmonary fibrosis research.
Article describing the concept and clinical applications of matrix-mimetic agents for corneal and other tissue repair, authored by clinicians and researchers.
Reference to a clinical study on an ophthalmic application of matrix-mimetic therapy published in JAMA Ophthalmology addressing corneal disease outcomes.
Article summarizing a topical treatment study assessing efficacy and tolerance of a matrix-mimetic agent in neurotrophic keratopathy.